1. J Hepatol. 2017 Apr;66(4):734-742. doi: 10.1016/j.jhep.2016.12.010. Epub 2016 
Dec 22.

Germline and somatic DICER1 mutations in familial and sporadic liver tumors.

Caruso S(1), Calderaro J(2), Letouzé E(1), Nault JC(3), Couchy G(1), Boulai 
A(1), Luciani A(4), Zafrani ES(5), Bioulac-Sage P(6), Seror O(7), Imbeaud S(1), 
Zucman-Rossi J(8).

Author information:
(1)INSERM, Unité Mixte de Recherche (UMR) 1162, Génomique Fonctionnelle des 
Tumeurs Solides, Equipe Labellisée Ligue contre le Cancer, Paris, France; 
Université Paris Descartes, Labex Immuno-Oncology, Sorbonne Paris Cité, Paris, 
France; Université Paris 13, Sorbonne Paris Cité, Unité de Formation et de 
Recherche (UFR) Santé, Médecine, Biologie Humaine (SMBH), Bobigny, France; 
Université Paris Diderot, Institut Universitaire d'Hématologie, Paris, France.
(2)INSERM, Unité Mixte de Recherche (UMR) 1162, Génomique Fonctionnelle des 
Tumeurs Solides, Equipe Labellisée Ligue contre le Cancer, Paris, France; AP-HP, 
Department of Pathology, CHU Henri Mondor, Créteil, France; Université Paris-Est 
Créteil, 94010 Créteil, France.
(3)INSERM, Unité Mixte de Recherche (UMR) 1162, Génomique Fonctionnelle des 
Tumeurs Solides, Equipe Labellisée Ligue contre le Cancer, Paris, France; 
Université Paris Descartes, Labex Immuno-Oncology, Sorbonne Paris Cité, Paris, 
France; Université Paris 13, Sorbonne Paris Cité, Unité de Formation et de 
Recherche (UFR) Santé, Médecine, Biologie Humaine (SMBH), Bobigny, France; 
Université Paris Diderot, Institut Universitaire d'Hématologie, Paris, France; 
AP-HP, Hôpitaux Universitaires Paris-Seine Saint-Denis, Site Jean Verdier, Pôle 
d'Activité Cancérologique Spécialisée, Service d'Hépatologie, Bondy, France.
(4)AP-HP, Department of Medical Imaging, CHU Henri Mondor, Créteil, France.
(5)AP-HP, Department of Pathology, CHU Henri Mondor, Créteil, France.
(6)INSERM, UMR 1053, Bordeaux, France; Université de Bordeaux, Bordeaux, France; 
CHU de Bordeaux, Pellegrin Hospital, Department of Pathology, Bordeaux, France.
(7)INSERM, Unité Mixte de Recherche (UMR) 1162, Génomique Fonctionnelle des 
Tumeurs Solides, Equipe Labellisée Ligue contre le Cancer, Paris, France; AP-HP, 
Radiology Department, Hôpital Jean Verdier, Hôpitaux Universitaires 
Paris-Seine-Saint-Denis, Bondy, France.
(8)INSERM, Unité Mixte de Recherche (UMR) 1162, Génomique Fonctionnelle des 
Tumeurs Solides, Equipe Labellisée Ligue contre le Cancer, Paris, France; 
Université Paris Descartes, Labex Immuno-Oncology, Sorbonne Paris Cité, Paris, 
France; Université Paris 13, Sorbonne Paris Cité, Unité de Formation et de 
Recherche (UFR) Santé, Médecine, Biologie Humaine (SMBH), Bobigny, France; 
Université Paris Diderot, Institut Universitaire d'Hématologie, Paris, France; 
AP-HP, Hôpital Européen Georges Pompidou, Paris, France. Electronic address: 
jessica.zucman-rossi@inserm.fr.

BACKGROUND & AIMS: Growing evidence suggests that genetic predisposition 
significantly increases the risk of hepatocellular carcinoma (HCC), 
independently from the presence of other risk factors. Here, we report a novel 
germline DICER1 mutation associated with familial recurrent liver tumors. We 
then aimed to investigate the contribution of constitutional and somatic DICER1 
mutations on HCC occurrence.
METHODS: We investigated two individuals of a single family that developed 
recurrent well-differentiated hepatocellular tumors over the years. Histological 
slides from surgically resected tumors were reviewed. Exome sequencing was 
performed on constitutional DNA from circulating lymphocytes in both patients. 
The presence of somatic DICER1 mutations was analyzed in 243 liver tumors. 
MicroRNA (miRNA) sequencing was performed in 50 liver tumors to identify groups 
of tumors with similar profiles and differentially expressed miRNAs (DEMs).
RESULTS: A pathological study identified hepatocellular adenomas and 
well-differentiated carcinomas in both patients. Tumors exhibited Wnt/β-catenin 
pathway activation, with strong and diffuse glutamine synthetase expression. 
Interestingly, non-tumor liver tissues showed abnormal liver zonation as 
previously reported in Dicer1 knockout mouse livers. Screening for DICER1 
mutations in 243 sporadic liver tumors identified six tumors with somatic DICER1 
mutations. In HCCs, DICER1 mutations were significantly associated with CTNNB1 
mutations (p=0.03). miRNA profiling identified a specific expression profile in 
DICER1-mutated tumors with a decreased expression of mature miRNAs compared to 
the other samples. Among the DEMs, downregulation of let-7a and miR-365b was 
closely related to DICER1 mutations.
CONCLUSIONS: Our results highlight the role of DICER1 mutations in liver 
carcinogenesis in a specific subtype of familial and sporadic hepatocellular 
carcinomas associated with β-catenin activation.
LAY SUMMARY: DICER1 germline mutations are known to predispose individuals to 
the development of malignant tumors, mainly pleuropulmonary blastoma and ovarian 
Sertoli-Leydig cell tumor. Here, we described familial HCC associated with a 
novel DICER1 germline mutation and altered liver zonation. Familial and sporadic 
HCCs carrying DICER1 mutations are associated with CTNNB1 mutation and 
characterized by a reduced expression of specific mature miRNAs.

Copyright © 2017 European Association for the Study of the Liver. Published by 
Elsevier B.V. All rights reserved.

DOI: 10.1016/j.jhep.2016.12.010
PMID: 28012864 [Indexed for MEDLINE]